New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SHPG;JNJ;MRK;PFE;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 14, 2015
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN PBR SU NFLX ALU BIDU TSLA JNJ GE
09:17 EDTJNJJohnson & Johnson says capital allocation strategy remains the same
The company says it continues to view dividends as its first priority in returning capital to shareholders. The company said it is still looking at portfolio for potential exits.
09:16 EDTJNJJohnson & Johnson says FY15 guidance doesn't include biosimilar compeition
Subscribe for More Information
09:16 EDTJNJJohnson & Johnson sees FY15 EPS constant currency $6.64-46.79
Sees FY15 adjusted EPS $6.04-6.19. The company had previously announced FY15 adjusted EPS $6.12-$6.27. FY15 EPS consensus $6.16
09:13 EDTJNJOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
08:57 EDTJNJJohnson & Johnson backs FY15 sales $75B-$76B
Including foreign exchange, sees reported sales $70B-$71B. Consensus is $71.16B. Backs FY15 net interest expense $450M-$550M. Raises FY15 net other income expense to $2B-$2.1B from $1.5B-$1.6B. Expects R&D tax credit will be renewed by Congress. Raises FY15 effective tax rate to 21%-22% from 20%-21%. If the tax credit is not approved, it will negatively impact the tax rate by 0.5%. Comments taken from Q1 earnings conference call.
07:50 EDTJNJJohnson & Johnson reports Q1 Worldwide Consumer sales $3.4B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson cuts FY15 adjusted EPS to $6.04-$6.19 from $6.12-$6.27
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 domestic sales up 5.9% to $8.69B
Subscribe for More Information
07:45 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.56, consensus $1.54
Subscribe for More Information
April 13, 2015
17:10 EDTJNJIBM establishes a Watson Health Cloud
Subscribe for More Information
16:21 EDTJNJOn The Fly: Top stock stories for Monday
Subscribe for More Information
15:38 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
07:20 EDTSHPGShire price target raised to $288 from $267 at JPMorgan
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use